BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ceplene histamine dihydrochloride: Additional Phase III data

A subset analysis of 190 patients who were aggressively treated with consolidation therapy before randomization in an international Phase III trial showed that Ceplene plus IL-2 non-significantly improved median overall survival (OS) by 36 months vs. standard of care (p=0.07). Maxim Pharmaceuticals Inc., which EpiCept acquired in 2005, previously reported...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >